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1. Introduction
The development of antiangiogenic 
agents (AAs) has yielded significant clin-
ical results in improved progression-free 
survival and overall survival. Ten new 
drugs (seven small kinase inhibitors, two 
antibodies, and one fusion protein) are 
approved by FDA for multiple cancer indi-
cators.[1] Photodynamic therapy (PDT) is 
a clinically approved, minimally invasive, 
light-triggered cancer therapeutic method, 
and the antivascular effects of PDT are 
known to contribute greatly to its efficacy.[2] 
Efforts have been made to combat cancers 
particularly with vascular-targeted PDT 
(VTP). Typically, VTP is performed by irra-
diating the target tissue a short duration 
after photosensitizer (PS) administration 
(e.g., 15 min after intravenous injection 
of PS). In this manner, the PS is passively 
distributed mainly in the vascular com-
partment.[3] The representative product, 
WST-11 (TOOKAD soluble, padeliporfin) 
developed by STEBA Biotech, has entered 
into phase III in Europe and recently been 
approved for use in early-stage prostate 
cancer in Mexico.[4] In order to strengthen 
Vascular-targeted photodynamic therapy (VTP) is a recently approved 
strategy for treating solid tumors. However, the exacerbated hypoxic 
stress makes tumor eradication challenging with such a single modality 
approach. Here, a new graphene oxide (GO)-based nanosystem for 
rationally designed, interlocking trimodal cancer therapy that enables VTP 
using photosensitizer verteporfin (VP) (1) with codelivery of banoxantrone 
dihydrochloride (AQ4N) (2), a hypoxia-activated prodrug (HAP), and 
HIF-1α siRNA (siHIF-1α) (3) is reported. The VTP-induced aggravated 
hypoxia is highly favorable for AQ4N activation into AQ4 (a topoisomerase 
II inhibitor) for chemotherapy. However, the hypoxia-induced HIF-1α 
acts as a “hidden brake,” through downregulating CYP450 (the dominant 
HAP-activating reductases), to substantially hinder AQ4N activation. 
siHIF-1α is rationally adopted to suppress the HIF-1α expression upon 
hypoxia and further enhance AQ4N activation. This trimodal nanosystem 
significantly delays the growth of PC-3 tumors in vivo compared to the 
control nanoparticles carrying VP, AQ4N, or siHIF-1α alone or their 
pairwise combinations. This multimodal nanoparticle design presents, the 
first example exploiting VTP to actively induce hypoxia for enhanced HAP 
activation. It is also revealed that HAP activation is still insufficient under 
hypoxia due to the hidden downregulation of the HAP-activating reductases 
(CYP450), and this can be well overcome by GO nanoparticle-mediated 
siHIF-1α intervention.
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the vascular-targeted efficacy, other attempts have involved con-
jugating vascular targeting ligands to the PS or PS nanocarrier 
to directly target the PS to tumor neovasculature.[5] The vas-
cular-targeting ligands like  tripeptide Arg-Gly-Asp (RGD) have 
been widely used to target nanoparticles to tumor vessels.[6]
However, tumor hypoxic stress will be inevitably exacerbated 
by the antivascular effects and oxygen consumption in the tumor 
microenvironment (TME) after PDT. This usually leads to com-
promised efficacy and clinical performance of PDT[3a,7] and other 
antiangiogenic strategies.[8] One emerging modality to overcome 
hypoxia and the associated stress response is to combine PDT 
with chemotherapy (chemophototherapy),[9] among which the 
combinations of PDT and AA have received more attention.[10] 
However, some preclinical attempts still yielded unsatisfactory 
outcome: 1) Compared to PDT alone, PDT followed with beva-
cizumab or sunitinib (two FDA-approved AAs) did not further 
impede tumor growth.[11] We speculate that the antivascular 
effects of PDT seriously prevented the tumor perfusion of the 
follow-up AAs. 2) While if the administration sequence was 
reversed, precedently dosed bevacizumab even antagonized 
the effects of the follow-up PDT.[11] This may be caused by the 
antiangiogenic effects of bevacizumab, which could either 
directly compromise the PS perfusion or aggravate hypoxia and 
thus extremely impair the potency of the oxygen-dependent PDT.
Here, we developed a new VTP-based strategy in which the 
VTP-induced hypoxia was smoothly exploited for enhanced 
cancer treatment. This was achieved by an engineered cyclo 
(Arg-Gly-Asp-D-Phe-Lys) (c(RGDfK)) peptides modified gra-
phene oxide (GO)-based nanosystem, codelivering verteporfin 
(VP), banoxantrone dihydrochloride (AQ4N), and HIF-1α siRNA 
(siHIF-1α) for trimodal combination therapy:
(1) VP is a photosensitizer with a long absorbance at 690 nm. 
VP-mediated PDT has been approved for age-related macu-
lar degeneration,[2] and also investigated against multiple 
cancers.[12]
(2) AQ4N is a representative hypoxia-activated prodrug (HAP). 
Besides hypoxia, the activation of AQ4N also depends on cy-
tochrome P450 (CYP450) activating reductases, which are also 
dominantly responsible for the activation of most other HAPs.[13] 
Two main CYP450 enzymes, CYP1A1 and 2B6, are shown to 
metabolize AQ4N into AQ4 (a potent inhibitor of topoisomer-
ase II) efficiently (Figure S1, Supporting Information).[14] How-
ever, O2 blocks this activation process by outcompeting AQ4N 
for heme-centered active site of CYP450, conferring the selectiv-
ity of AQ4N in eradicating hypoxic tumor cells.[15]
Unfortunately, the development of multiple HAPs is 
experiencing bottleneck in clinical trials.[13b] One major hin-
drance is the low levels of hypoxia in heterogeneous tumor 
microenvironment,[13b,16] which leads to low efficient activation 
of HAPs. In this study, we aimed to use VP-mediated VTP to 
actively induce aggravated hypoxia in tumor sites and enhance 
AQ4N activation.
(3) Elevated HIF-1α expression is one of the most important 
events under tumor hypoxic stress, which mediates various 
adaptive responses for tumor to survive under hypoxia.[13a] 
Noticeably, HIF-1α can also downregulate CYP450 via 
competitive binding with HIF-1β against aryl hydrocarbon 
receptor (AhR).[17] In this manner, HIF-1α actually acts as a 
“hidden brake” to substantially hinder AQ4N activation un-
der hypoxia. However, this issue has not ever been consid-
ered in the previous report involving nanoparticle-mediated 
combination therapy of PDT and AQ4N.[18] We here adopted 
siHIF-1α to suppress HIF-1α, therefore upregulate CYP450, 
and enhance the AQ4N activation under hypoxia.
We chose GO as the nanoscaffold, as it is well biocompat-
ible and has been widely used as multifunctional nanocar-
rier for drug and gene delivery.[19] VP and AQ4N were closely 
absorbed on GO through π–π stacking and hydrophobic inter-
actions. siHIF-1α was efficiently condensed on the polyethyl-
enimine (PEI) which was linked to GO by N-(3-Dimethylami-
nopropyl-N’-ethylcarbodiimide) hydrochloride/N-hydroxysul-
fosuccinimide sodium salt chemistry. c(RGDfK) peptides are 
classical high avidity (Kd ≈ 40 × 10−9 m) ligands to target αvβ3,[20] 
overexpressed on the surface of tumor vascular endothelial 
cells (ECs) and many tumor cells such as PC-3 prostate cancer 
cells.[21] The RGD modification-mediated nanoparticle uptake 
in αvβ3 expressed cells has been widely proved in previous 
reports.[22] c(RGDGfK)-capped eight-arm polyethylene glycol 
(PEG) used here conferred both the stealth property and tumor 
vessel and tumor cell dual-targeted merits of the nanosystem.
We hypothesize that (1) VP-mediated VTP can lead to 
aggravated hypoxia through antivascular effects, which can be 
smartly used for highly effective AQ4N activation into AQ4 
for enhanced chemotherapy; and (2) siHIF-1α can suppress 
HIF-1α expression upon VTP-induced acute hypoxia, and fur-
thermore increase the levels of CYP1A1 and 2B6 essential for 
AQ4N activation. Our strategy is proved to be effective in a 
prostate cancer model. The working model of the mechanism-
based, interlocking trimodal GO-based nanosystem is schemat-
ically illustrated in Figure 1.
Previous nanoparticle-based research mainly focused on 
relieving tumor hypoxia to enhance chemotherapy, radiotherapy, 
or PDT.[23] Typically, using calatase to produce endogenous H2O2-
derived O2[24] or perfluorocarbon to delivery exogenous O2[25] 
are two main methods. Several efforts were also made to uti-
lize hypoxia,[23] such as HAPs therapy[18,26] or hypoxia-triggered 
drug delivery.[27] However, to the best of our knowledge, this 
is the first effort exploiting VTP (a clinically relevant strategy) 
to induce hypoxia for successfully enhanced HAP activation. 
This smart design for the combination of VTP and HAP holds 
promise for clinical translation and meanwhile overcoming their 
respective limitation of single modality approach. Moreover, the 
important ‘hidden brake’ role of increased HIF-1α upon hypoxia 
in hindering HAP activation by downregulating CYP450 is first 
revealed, and this issue is well solved in this study through using 
the GO nanoparticle-mediated siHIF-1α intervention.
2. Results
2.1. Nanoparticle Characterization and Cellular Uptake
The trimodal nanosystem was stepwise engineered as illus-
trated in Figure 2A. The three active molecules (VP, AQ4N, 
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and siHIF-1α) were coloaded onto c(RGDfK) modified nano-
GO, forming a targeted combination nanosystem, namely 
c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α. The loading of VP and 
AQ4N on the nanoparticles was identified and quantified with 
UV–vis–NIR absorbance detection, and the absorbance peaks 
were at 410 nm for VP and 610 nm for AQ4N (Figure S2, Sup-
porting Information). The drug loading (DL%) was 7% for VP 
and 35% for AQ4N. The electrophoretic mobility shift assay 
indicated that the complete adsorption of siHIF-1α on the 
c(RGDfK)-ppGO/VP-AQ4N was obtained when the N/P ratio 
was greater than 40 (Figure 2B). Thus, N/P of 40 was selected 
in the following study involved with nanoparticles containing 
siRNA. Atomic force microscopy (AFM) images showed that 
the nanosystem had a sheet structure (Figure 2C), and the thick-
ness 1–2 nm indicated a structure characteristic of a single or 
two layered sheets (Figure 2D), according to previous work.[28] 
This nanosystem had hydrodynamic size of 91.3 nm and zeta 
potential of 16.2 mV (Table S1, Supporting Information).
The nanosystem had good colloidal stability in phosphate 
buffered saline (PBS; pH 7.4, 0.01 m) and PBS containing 10% 
fetal bovine serum (FBS) (Figure 2E). Also, it slowly released 
VP and AQ4N with relatively low burst release, implying the 
less drug leakage before the nanoparticles target to the tumor 
in vivo (Figure S3, Supporting Information). Other nanoparti-
cles carrying only one molecule or their pairwise combinations, 
as well as the empty nanocarrier, were also prepared when the 
corresponding molecules were included during the prepara-
tion. Their sizes and zeta potentials were also measured using a 
Zetasizer Nano ZS instrument (Table S1, Supporting Informa-
tion). The contents of PEI and PEG in the nanocarrier (ppGO) 
were also quantified. PEI was determined to be –36% (w/w) 
by assaying the cuprammonium complex formed by PEI and 
copper (II) ions at 285 nm (Figure S4, Supporting Informa-
tion).[29] The PEG content was determined to be –15% (w/w), 
using the PEGylated protein ELISA kit (Enzo Life Sciences, 
Farmingdale, NY, USA).[30] The c(RGDfK) content in the tar-
geted nanocarrier (c(RGDfK)-ppGO) was estimated to be –3.4% 
(w/w) through determining the conjugated peptides using the 
CBQCA Protein Quantitation Kit (Thermo Fisher Scientific, 
Shanghai, China).[31]
Efficient nanoparticle uptake in the targeted cells is impor-
tant for VP, AQ4N, and siHIF-1α to exert their activity, as 
all their targets locate inside the cells. We then evaluated the 
uptake of the nanocarrier, using the VP as the fluorescent 
probe, in human umbilical vein endothelial cells (HUVECs) or 
PC-3 cells, both of which highly express integrin αvβ3.[21,32] As 
expected, c(RGDfK) peptides improved the nanoparticle uptake 
in HUVECs and PC-3 cells at both low (10 µg mL−1) and high 
(50 µg mL−1) nanoparticle concentrations, conferring the dual-
targeting property (Figure 2F,G).
2.2. Targeted Photodynamic Toxicity to Both HUVECs 
and PC-3 Cells
Next, we evaluated if the targeted cellular uptake can con-
tribute significant VP-mediated phototoxicity to both HUVECs 
and PC-3 cells. The production of singlet oxygen was detected 
using danthracene-9,10-diyl-bis-methylmalonate (ADMA) to 
verify the PDT performance (Figure S5, Supporting Informa-
tion).[33] It showed photodynamic treatment with c(RGDfK)-
ppGO/VP (690 nm, 30 mW cm−2, 10 min) resulted in much 
higher toxicity to both HUVECs and PC-3 cells compared to 
nontargeted ppGO/VP at VP concentrations of 0.01–1 × 10−6 m 
Adv. Sci. 2018, 5, 1800034
Figure 1. Schematic illustration of the working model of the interlocking trimodal graphene-oxide-based nanosystem. 1) The trimodal nanosystem, 
c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α, targets to the PC-3 tumors after being intravenously injected into the mice. 2) VP-based VTP with 690 nm irradia-
tion results in tumor vessel occlusion and aggravated hypoxia, 3) which effectively activates AQ4N into cytotoxic AQ4. 4) However, the increased HIF-1α 
upon VTP downregulates CYP450 activating reductases, acting as a “hidden brake” to prevent AQ4N activation under hypoxia. Through knocking down 
HIF-1α, the codelivered siHIF-1α can upregulate CYP450 expression to further strengthen AQ4N activation.
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(Figure 3A,D). These results were in agreement with the obser-
vation of calcein-AM and PI dual staining assay (Figure 3C,F). 
Noticeably, HUVECs were much more sensitive to PDT treat-
ment than PC-3 cells. Around 50% PC-3 cells remained viable 
after light irradiation with 1 × 10−6 m VP from c(RGDfK)-ppGO/
VP; however, almost all HUVECs lost their viabilities under the 
same condition. The superior damage to the endothelial cells is 
the requisite for VTP-induced tumor vessel occlusion and blood 
stasis, and the injury to the PC-3 tumor cells may partially ben-
efit for inhibiting the tumor growth. Both c(RGDfK)-ppGO/VP 
and ppGO/VP without 690 nm laser irradiation caused much 
less toxicity to the two targeted cells, implying that ppGO is 
well biocompatible, and the VP-mediated phototoxicity domi-
nantly contributed the cytotoxicity (Figure 3B,E).
2.3. Lysosomal Escape, Protein Expression of HIF-1α  
and CYP450, and AQ4N Cytotoxicity in PC-3 Cells
Efficient escape from lysosomes into the cytosol is vital for non-
viral gene delivery nanocarrier, which can prevent the siRNA 
from degradation by lysosomal nucleases.[34] The trafficking of 
Adv. Sci. 2018, 5, 1800034
Figure 2. Preparation and characterization of the trimodal nanosystem. A) Schematic illustration of the preparation process. Note: pGO, PEG-GO; 
ppGO, pGO conjugated with PEI. B) Electrophoretic mobility shift assay of the siHIF-1α complexed with c(RGDfK)-ppGO/VP-AQ4N at different N/P 
ratios. C) AFM photograph (bar, 500 nm). D) The height profile of the AFM image showed that the nanosystem was 1–2 layered sheets. E) Colloid 
stability of the nanosystem in PBS and PBS with 10% FBS after 24 and 48 h incubation at 37 °C. The data are presented as means ± s.d. of three inde-
pendent replicates. The nanoparticle uptake in F) HUVECs and G) PC-3 cells after 2 h incubation at 37 °C was observed and assayed by quantifying 
the intracellular fluorescence intensity on the Thermo Scientific ArrayScan XTI High Content Analysis Reader. The VP (Ex: 650 nm, Em: 690 nm) was 
used as the fluorescent probe. The mean ± s.d. from four independent replicates is shown. **p < 0.01, ***p < 0.001.
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the c(RGDfK)-ppGO/FAM-siHIF-1α in PC-3 cells was inves-
tigated under confocal laser scanning microscopy (CLSM) 
(Figure 4A). At 0.5 and 1 h, we can see fluorescent green dots 
(FAM-siHIF-1α condensed on the nanoparticles) appeared in 
the cells. At 2 h, the co-localization (yellow) of the green dots 
and the red LysoTracker-labeled lysosomes can be well observed, 
showing the trapping of the siHIF-1α-condensed nanocarrier 
inside the lysosomes. At 4 h, diffusive green regions instead of 
spotty fluorescence signaling spread inside the cytosol. In this 
scenario, most of the lysosomes were swelled and ruptured, 
and could not be well labeled with LysoTracker.[35] Here, PEI 
offered the “proton sponge” effect for the successful escape of 
the nanoparticles from the lysosomes and the follow-up effi-
cient release of free FAM-siHIF-1α in the cytoplasm.
Adv. Sci. 2018, 5, 1800034
Figure 3. The viabilities of HUVECs and PC-3 cells after photodynamic treatment with c(RGDfK)-ppGO/VP or ppGO/VP. The viabilities of A,B) HUVECs 
and D,E) PC-3 cells after treated with the nanoparticles and light irradiation (690 nm, 30 mW cm−2, 10 min) or not were evaluated using CCK-8 assay. 
C) HUVECs and F) PC-3 cells after PDT treatment with the nanoparticles containing 1 × 10−6 m VP were stained with LIVE/DEAD cell viability/cytotox-
icity kit. The representative photographs of the cells were shown. Bar, 25 µm. The mean ± s.d. from three independent replicates is shown. *p < 0.05, 
**p < 0.01.
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Then, we investigated if the delivered siHIF-1α could sup-
press HIF-1α expression under hypoxia and thereafter upreg-
ulate the contents of CYP1A1 and 2B6 (two main AQ4N acti-
vating enzymes),[14] because HIF-1α can take away the availa-
bility of HIF-1β for AhR binding and thereafter reduce CYP450 
expression (Figure 4B).[17] We assayed the expression of HIF-
1α and CYP1A1 and 2B6 using Western blot (Figure 4C–F). 
It showed that siHIF-1α significantly decreased the HIF-1α 
expression in hypoxic PC-3 cells, and this effect was more 
obvious as for the c(RGDfK)-modified targeted nanosystem. 
Consistent with previous reports,[17,36] HIF-1α inhibition led 
to increased expressions of CYP1A1 and 2B6, which can be 
favorable for AQ4N activation.[13a]
We then examined if siHIF-1α could directly increase the 
AQ4N cytotoxicity. As expected, the involvement of siHIF-1α 
significantly enhanced the AQ4N toxicity to hypoxic PC-3 
cells (Figure 4G). These results may be ascribed to the role 
of siHIF-1α in upregulating the CYP450 enzymes in PC-3 
cells (Figure 4B–F). Noticeably, siHIF-1α alone did not cause 
obvious cytotoxicity under the tested condition (Figure 4G).
We also explored the effects of the exogenously added 
CYP450 enzymes on AQ4N cytotoxicity (Figure 4H). It showed 
that under hypoxia, the AQ4N toxicity to PC-3 cells was dra-
matically increased in the presence of CYP450 enzymes from 
rat liver microsomes, and this effect was more obvious in the 
cells treated with the c(RGDfK)-modified targeted nanopar-
ticles. Although hypoxia alone without the added CYP450 
also increased the AQ4N cytotoxicity; however, this effect was 
relatively weak. These results proved that increased CYP450 
enzymes are extremely beneficial for enhanced AQ4N activation 
and cytotoxicity under hypoxia, which are in good agreement 
with previous literature.[37]
Adv. Sci. 2018, 5, 1800034
Figure 4. Lysosomal escape, protein expression of HIF-1α and CYP450, and AQ4N cytotoxicity in PC-3 cells. A) Intracellular trafficking of FAM-labeled 
siHIF-1α (green, Ex: 488 nm, Em: 520 nm) loaded in c(RGDfK)-ppGO was observed using CLSM. The co-localization (yellow dots indicated with 
white arrows) of the green dots and the red LysoTracker-labeled lysosomes (Ex: 577 nm, Em: 590 nm) appeared at 2 h, showing the trapping of the 
siHIF-1α-condensed nanocarrier inside the lysosomes. The lyososomal escape was observed at 4 h after incubation. Note that at this time most of 
the lysosomes were swelled and ruptured, and could not be well labeled with LysoTracker. Bar, 10 µm. B) Schematic illustration of the mechanism 
how hypoxia negatively regulates CYP450. HIF-1β, also known as AhR (aryl hydrocarbon receptor) nuclear translocator, can partner with AhR and NFI 
(nuclear factor 1) to form a heterotrimer and then binds to the promoter of CYP450 genes. However, hypoxia leads to high expression of HIF-1α, which 
can translocate into the nucleus where it dimerizes with HIF-1β, thus decreases the availability of HIF-1β and causes a downregulation of CYP450. 
C) Western blot assay indicated that the expressions of HIF-1α and CYP1A1 and 2B6 (two main AQ4N activating reductases) in hypoxic PC-3 cells 
showed the opposite changing trend after siHIF-1α treatment. siNC, negative control siRNA with a scrambled sequence. D–F) Statistical assay of the 
relative protein contents. The data are presented as means ± s.d. (n = 3), ***p < 0.001. G) siHIF-1α (150 × 10−9 m) increased the AQ4N toxicity to 
hypoxic PC-3 cells, although it alone was nontoxic at the tested dose. The data are presented as means ± s.d. (n = 3) ***p < 0.001. H) Exogenously 
added CYP450 enzymes from rat liver microsomes were beneficial for AQ4N-mediated toxicity to hypoxic PC-3 cells. The cell viabilities were detected 
using CCK-8 assay. The data are presented as means ± s.d. (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001.
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2.4. Targeted Distribution of the c(RGDfK)-Modified 
Nanosystem in PC-3 Xenograft
Next, we investigated the in vivo tumor targeting feature of 
the c(RGDfK)-conjugated nanosystem. It showed that at 2 h 
after i.v. injection, the accumulation of Cy7-labeled c(RGDfK)-
ppGO in PC-3 tumors was around sevenfold higher than that 
of the nontargeted control nanoparticles (Figure 5A,B), and this 
increased distribution pattern maintained for the study dura-
tion (24 h after injection) (Figure 5, and Figure S6, Supporting 
Information). Furthermore, free c(RGDfK) peptides could 
almost completely block the improved distribution, indicating 
the dominant contribution of the ligands to the targeting prop-
erty of the nanosystem. Oku and co-workers previously have 
revealed that tumor vessel-targeted liposomal VP (APRPG-
PEG-Lip BPD-MA) at 3 h after i.v. injection already accurately 
targeted and accumulated in the tumor vascular ECs, conferred 
dramatically enhanced distribution in tumor sites, and earned 
superior antitumor efficacy through the VTP compared to the 
nontargeted ones.[38] Given the remarkably increased intratu-
moral distribution of our c(RGDfK)-modified nanosystem at 
2 h after injection, and that the reported similar duration (3 h) 
after injection has been proved significantly effective in lipo-
somal VP-mediated VTP, we then selected 2 h after nanopar-
ticle injection for following in vivo VTP and antitumor tests. 
The targeted distributions of the three loaded cargoes (VP, 
AQ4N, and siHIF-1α) were also identified (Figures S7–S9, Sup-
porting Information).
2.5. Targeted Trimodal Nanosystem with 690 nm Irradiation 
Decreased Functional Tumor Vessels and Tumor Perfusion
It has been well established that VTP can cause tumor vessel 
occlusion and blood stasis.[2,39] We then carefully characterize 
the proportion of functional vessels and the profiles of vascular 
perfusion in tumors after VTP. The functional vessels were 
detected using the FITC-labeled lectin (green) (Figure 6A). 
This probe can well bind to the complex-type N-glycans glyco-
proteins, particularly the poly-N-acetyllactosamine residues of 
complex carbohydrates of the endothelial plasmalemma.[40] The 
tumor sections were also stained with CD31 antibodies (red) to 
mark all the vascular structures (Figure 6A). At 24 h after light 
irradiation, the proportions of lectin+CD31+ functional vessels 
was ≈9% in the tumors treated with the targeted trimodal nano-
system, in contrast to 55% with the nontargeted nanosystem 
(ppGO/VP-AQ4N-siHIF-1α) and 65% with the empty vehicle 
(c(RGDfK)-ppGO) (Figure 6A,B). Such significant difference 
still maintained at 48 h. In sharp contrast, the functional 
tumor vessels were well maintained if no irradiation was given 
(Figure 6A,B). These observations definitely demonstrated that 
VTP treatment shut down the tumor vessel network.
Tumor perfusion was explored using the Vevo 2100 micro-
ultrasound imaging system (Figure 6C,D). 24 h after light 
irradiation, the ultrasound signal was significantly decreased 
in the tumors treated with the targeted trimodal nanosystem, 
indicating the low perfusion in the tumor sites. Quantification 
of the perfusion parameters (Wash-in Area Under the Curve, 
Peak Enhancement, Wash-in Perfusion index) showed that the 
targeted trimodal nanosystem with light irradiation was able to 
effectively block the tumor perfusion compared to the nontar-
geted control and empty vehicle (Figure 6E–G). These results 
were also well consistent with the observations on the func-
tional vessels (Figure 6A,B).
2.6. Targeted Trimodal Nanosystem with 690 nm Irradiation 
Aggravated Tumor Hypoxia, Suppressed HIF-1α, Upregulated 
CYP450, and Increased AQ4N Activation into AQ4 in Tumors
We then investigated if the occlusion of the functional ves-
sels and declined tumor perfusion after irradiation can lead to 
aggravated hypoxia. Tumor pO2 at 24 and 48 h after irradiation 
was examined using an Oxylite fiber-optic oxygen sensor 
(Figure 7A). The intact PC-3 tumors at the used size were 
hypoxic (pO2 8.7 mmHg), which was in sharp contrast with the 
significantly higher oxygen level (normoxia) in the muscle of 
mice hind legs (31.0 mmHg) (Figure S10, Supporting Informa-
tion). It showed tumor pO2 remained high around 10 mmHg 
in the absence of VP, and siHIF-1α or AQ4N treatment did 
not influence the pO2. However, the pO2 declined to below 
1 mmHg when VP was involved in the targeted c(RGDfK)-
modified nanoparticles. The pO2 was 0.4 mmHg in the group 
of targeted trimodal nanosystem, in contrast to 5.2 mmHg 
Adv. Sci. 2018, 5, 1800034
Figure 5. c(RGDfK) modification facilitated the nanoparticle accu-
mulation in tumors. A) Male BALB/c nude mice bearing PC-3 tumor 
(150 mm3) were given a single intravenous injection of Cy7-labeled tar-
geted or nontargeted nanoparticles (containing Cy7 0.4 mg kg−1). The 
mice in another group were coinjected with targeted nanoparticle and 
50-fold molar excess free c(RGDfK) peptides. Mice with in vivo Cy7 fluo-
rescence were imaged at per-determined time after injection using the 
Xenogen IVIS 200 system, and the representative images at 2 h were 
shown. The tumors were indicated in yellow circles. B) Statistical assay 
of the fluorescence intensity in the tumor regions at 1, 2, 8, and 24 h 
after injection. Data are presented as mean ± s.d. (n = 3) ***p < 0.001 
compared to the other two groups.
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for the nontargeted control (ppGO/VP-AQ4N-siHIF-1α) and 
9.3 mmHg for empty vehicle (c(RGDfK)-ppGO) at 24 h postir-
radiation. The pO2 in the tumors treated with targeted trimodal 
nanosystem maintained very low at 48 h (0.6 mmHg), confer-
ring a long-lasting hypoxic condition for AQ4N activation.
Next, we examined the expression of HIF-1α, and CYP1A1 
and 2B6 in tumors using Western blot (Figure 7B–E). It showed 
that the HIF-1α expression in the group of targeted trimodal 
nanosystem was remarkably suppressed to ≈30%, 20%, and 
15% level of those of the nontargeted control, targeted nano-
system without siHIF-1α (c(RGDfK)-ppGO/VP-AQ4N), and 
the intact hypoxic PC-3 cells, respectively (Figure 7B,C). Most 
importantly, the strong inhibition of HIF-1α led to 4–7.5-fold 
higher contents of CYP1A1 or 2B6 proteins compared to all the 
controls (Figure 7B,D,E). This change would be very helpful for 
AQ4N activation.
To investigate if such favorable changes in pO2 and CYP450 
activating enzymes in tumors can strengthen AQ4N activation 
in vivo, we quantified the intratumoral AQ4 concentrations 
using the established HPLC-MS/MS method (Figure 7F, and 
Figure S11, Supporting Information). Treatment without VP 
involved, such as c(RGDfK)-ppGO/AQ4N and c(RGDfK)-ppGO/
AQ4N-siHIF-1α, only conferred extremely low AQ4 contents 
(<0.1 µg g−1) in tumors, which was in sharp contrast to any 
Adv. Sci. 2018, 5, 1800034
Figure 6. Targeted trimodal nanosystem with 690 nm irradiation resulted in decreased functional vessels and tumor perfusion. A) Tumor vessels were 
stained by i.v. injection of FITC-labeled lectin (green) to mark perfused vessels, and the tumor sections were stained with CD31 antibodies (red) to 
mark all vascular structures. Bar, 50 µm. B) Statistical assay of the percent of lectin+CD31+ functional vessels compared to whole tumor vessels. Data 
are presented as mean ± s.d. (n = 3) ***p < 0.001. Tumor vascular perfusion was examined using the Vevo 2100 micro-ultrasound imaging system at 
24 h after irradiation. The perfusion images at the baseline C) before the injection of contrast agent and D) at the moment of the strongest contrast 
signal were shown in three different visualization display. B-mode (brightness mode) was acquired as original data.Maximum intensity persistence 
(MAP) mode showed the microvascular network distribution. Pseudo-color parametric mode displayed the intensity of perfusion kinetics. Tumors are 
outlined in green circles. Bar, 2.5 mm. Three representative parameters, E) Washing-in Area Under the Curve (WiAUC), F) Peak Enhancement (PE), 
and G) Wash-in Perfusion Index (WiPI) G) were statistically quantified using the Vevo LAB 1.7 software. Data are presented as mean ± s.d. (n = 3) 
**p < 0.01, ***p < 0.001.
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other treatments containing VP, demonstrating the importance 
of VP-mediated VTP for hypoxia induction and AQ4N activation 
(Figure 7A,F). The positive effect of siHIF-1α on AQ4N acti-
vation in tumors was also observed. At 48 h after irradiation, 
almost twofold AQ4 concentration was found in the tumors 
treated with the targeted trimodal nanosystem compared to 
that of control without siHIF-1α (c(RGDfK)-ppGO/VP-AQ4N) 
(Figure 7F). Such effect of siHIF-1α can be ascribed to its role 
of upregulating CYP1A1 and 2B6 prodrug-activating enzymes 
(Figure 7B–E). It is also noticed that at 24 h after irradiation, 
no more AQ4 in tumors was obtained in the group of targeted 
trimodal nanosystem (Figure 7F), which may be ascribed to the 
moderate changes in the HIF-1α inhibition and CYP450 upreg-
ulation in this duration (Figure S12, Supporting Information).
The targeted trimodal nanosystem resulted in 3.1- and 
4.5-folds higher AQ4 concentrations in tumors compared to 
nontargeted ppGO/VP-AQ4N-siHIF-1α, at 24 and 48 h after 
irradiation (Figure 7F). These results were well related with the 
observation of pO2 and CYP1A1 and 2B6 contents in the tumor 
sites at the same time (Figure 7A–E). Besides, the superior 
distribution mediated by the c(RGDfK) peptides of the targeted 
nanosystem compared to that of the nontargeted control may 
also contribute to the higher AQ4 contents in tumors (Figure 5).
2.7. Anticancer Effect of Targeted Trimodal Nanosystem 
in PC-3 Tumor-Bearing Mice
We then evaluated the anticancer efficacy of the targeted tri-
modal nanosystem in PC-3 tumor-bearing mice (Figure 8A). 
In this study, we carefully set complete controls, including 
the c(RDGfK)-modified nanosystem loading VP, AQ4N or 
siHIF-1α alone or their pair combinations. Saline, empty 
vehicle (c(RGDfK)-ppGO), and nontargeted control (ppGO/
VP-AQ4N-siHIF-1α) were also included. Beside tumor growth 
profiles (Figure 8B), we further quantified the doubling time 
(DT) of tumor volume (Figure 8C).
It showed nanosystem with VP alone could obviously extend 
the DT (7.2 d) compared to saline (DT 5.9 d) and c(RGDfK)-
ppGO (empty nanocarrier, DT 6.0 d), demonstrating the 
Adv. Sci. 2018, 5, 1800034
Figure 7. Targeted trimodal nanosystem with 690 nm irradiation decreased tumor pO2, inhibited HIF-1α expression, upregulated CYP450 expression, 
and induced more AQ4N activation into cytotoxic AQ4 in tumors. A) Tumor partial oxygen pressure (pO2) at 24 and 48 h after irradiation (690 nm, 
50 mW cm−2, 20 min) was examined using an Oxylite fiber-optic oxygen sensor. B) 48 h after irradiation, three nude mice from each group were sacri-
ficed. The PC-3 tumors were excised for Western blot assay of the HIF-1α, CYP 1A1, and 2B6 proteins. The PC-3 cells alone under hypoxia were used as 
control. C–E) Statistical analysis of the relative expression level of the three proteins in tumors. Data are presented as mean ± s.d. (n = 3) **p < 0.01, 
***p < 0.001. F) The AQ4 concentrations in tumors were determined using LC-MS/MS method at 24 and 48 h after irradiation. Data are presented as 
mean ± s.d. (n = 3) ***p < 0.001. n.s., not significant.
www.advancedsciencenews.com
1800034 (10 of 15) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
potency of VTP in cancer treatment. However, AQ4N alone (DT 
6.1 d) was moderately effective at the tested dose, which may 
be due to its extremely low activation under the relatively high 
pO2 in tumors (Figure 7A,F). siHIF-1α alone (DT 6.1 d) only 
displayed slight effect compared to saline. This may be ascribed 
to the relatively high pO2 (Figure 7A), thus low hypoxic stress 
pressure, which was not a suited circumstance for siHIF-1α to 
exhibit its effect.
In the dual-drug combination treatments, AQ4N plus 
siHIF-1α still conferred moderate effect (DT 6.2 d); this can be 
explained by the respective weak effects of the two molecules 
as discussed above. However, siHIF-1α plus VP significantly 
delayed the tumor growth and increased the DT (7.7 d) com-
pared to the VP or siHIF-1α alone. This result suggested that 
the role of siHIF-1α in inhibiting tumor growth via knocking 
down HIF-1α would be more obvious under aggravated 
hypoxic stress condition, such as that induced by VP-mediated 
VTP (Figure 7A). VP plus AQ4N led to dramatically enhanced 
anticancer effect with DT of 9.9 d, exhibiting the great contribu-
tion of AQ4N in delaying tumor growth when exposed under 
the severe hypoxia induced by VP-mediated VTP (Figure 7A).
As expected, the targeted VP, AQ4N, and siHIF-1α combina-
tion (trimodal nanosystem) earned the best effect of delaying 
tumor growth and extending the DT compared to all the 
single-drug or dual-drug treatments. The resulted DT (17.7 
d) was 2.9-, 2.3-, and 1.8-folds longer than that of AQ4N plus 
siHIF-1α, VP plus siHIF-1α, and VP plus AQ4N, respectively. 
Such advantage can be ascribed to the mechanism-based inter-
locking effects of the three molecules as previously discussed 
in the in vitro and in vivo tests, and as illustrated in Figure 1. 
Furthermore, such extended DT was 2.4-folds longer than that 
of nontargeted three-drug combination (DT 7.4 d). This can 
be ascribed to the c(RGDfK) ligands, which conferred the tar-
geted nanoparticle distribution in tumor sites (Figure 5) and 
improved nano particle intracellular uptake (Figure 2F,G) to 
enhance the effects of the three molecules. Moreover, this dra-
matically enhanced antitumor efficacy of the targeted trimodal 
nanosystem was not accompanied with overt toxicity such as 
loss of body weight (Figure 8D).
Histopathological examination showed that the targeted 
trimodal nanosystem led to much more karyopyknosis and 
karyorrhexis, the morphological features of apoptosis,[41] in 
the tumor cells (Figure S13A,B, Supporting Information). 
Moreover, such treatment resulted in much more TUNEL-
positive cells (Figure S13C,D, Supporting Information) and less 
PCNA-positive cells (Figure S13E,F, Supporting Information) in 
tumors compared to those of all the other controls.
3. Discussion
Cancer combination therapy can be clinically beneficial due 
to the comprehensive effects of increasing therapeutic effi-
cacy and lowering the required dose, hence side effects or tox-
icity.[42] Hypoxia is one of the hallmarks of solid tumor, and is 
considered as an important therapeutic target in cancer treat-
ment. Developing strategies to relieve or exploit hypoxia is an 
emerging attractive field in cancer nanotechnology. To the best 
of our knowledge, this study presented the first example using 
VTP, a clinically relevant strategy, to actively induce aggravated 
hypoxia for enhanced HAP activation and anticancer therapy. 
However, hypoxia also leads to the downregulation of CYP450 
Adv. Sci. 2018, 5, 1800034
Figure 8. Trimodal nanosystem delayed PC-3 tumor growth without causing loss of body weight. A) Schematic regimen of the treatment with various 
nanosystems. At day 1, 2 h after nanoparticle injection, the tumors were irradiated with laser only once (690 nm, 50 mW cm−2, 20 min). Then, tumor 
sizes and mice body weight were monitored for 2 weeks till day 15. B) Tumor growth profiles till day 15. a) c(RGDfK)-ppGO/VP versus saline and 
c(RGDfK)-ppGO. b) c(RGDfK)-ppGO/VP-siHIF-1α versus c(RGDfK)-ppGO/VP. c) c(RGDfK)-ppGO/VP-AQ4N versus c(RGDfK)-ppGO/VP-siHIF-1α. 
d) c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α versus all other groups. C) Tumor volume doubling time (DT) was noted on the top of each column. D) Mice 
body weight throughout the study. The data are presented as mean ± s.d. (n = 5) **p < 0.05, ***p < 0.001.
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(the dominant HAP-activating reductases) through the induced 
HIF-1α, which eventually compromises the HAP activation 
efficacy. This important hidden negative effect of hypoxia on 
CYP450 and HAP activation has not ever been considered in 
previous reports, and this issue is highlighted and well resolved 
in our research. All these were successfully accomplished with 
the engineered targeted trimodal graphene-oxide-based nano-
system (c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α).
Restrained HAP activation in vivo is often encountered due 
to the heterogeneous TME, which cannot offer required low 
pO2.[13a] We here developed a new method to promote HAP 
activation by actively inducing hypoxia via VTP. This was 
achieved by using c(RGDfK)-modified VP-loaded nanoparticle 
that can target integrin αvβ3 on tumor vascular ECs. As a facile 
in vitro model, tumor spheres have been used to evaluate the 
effects of drug and nanoparticles on cancer therapy.[43] How-
ever, there is so far no such model that involves both tumor 
cells and vascular system with perfused blood. Therefore, we 
focused the in vivo tests to carefully investigate the influence of 
VP on AQ4N activation. It showed that VP-based VTP in vivo 
led to serious blood occlusion, which was proved in the obser-
vation of dramatically decreased functional tumor vessels and 
perfusion (Figure 6). In vitro VTP with HUVECs as tumor vas-
cular EC model also confirmed the targeted damage to tumor 
vascular ECs (Figure 3A–C). Such antivascular effects and 
induced aggravated hypoxia (Figure 7A) compelled much more 
AQ4N activation into AQ4, which was shown when comparing 
the intratumoral AQ4 contents between the nanosystem con-
taining AQ4N alone and the one carrying both VP and AQ4N 
(Figure 7F).
However, hypoxic stress also leads to high expression of 
HIF-1α, which acts as “hidden brake” to substantially hinder 
AQ4N activation through downregulating CYP450 activating 
reductases. Here, we adopted siHIF-1α to effectively suppress 
HIF-1α, therefore increase CYP450 in hypoxic tumor cells, and 
further enhance AQ4N activation. The influence of siHIF-1α 
on AQ4N was evaluated both in vitro and in vivo. It showed 
that siHIF-1α significantly enhanced the cytotoxicity of AQ4N 
to hypoxic PC-3 cells, although siHIF-1α alone was nontoxic 
to the cells (Figure 4G). This effect of siHIF-1α can be related 
with its role of upregulating the AQ4N-activating reductases 
(CYP1A1 and 2B6) (Figure 4B–F). As AQ4N activation depends 
on both hypoxia and reductase (CYP450) (Figure 4H),[37b] the 
influence of siHIF-1α on in vivo AQ4N activation presented 
VP-dependent pattern. Without VP-mediated VTP, siHIF-1α 
could not increase the AQ4N activation in tumors (Figure 7F), 
as the relatively high pO2 (less hypoxia) in the tumors already 
seriously hindered AQ4N activation (Figure 7F). However, with 
the involvement of VP-mediated VTP, the effect of siHIF-1α 
on AQ4N activation in tumors could be obviously observed. 
At 48 h, nearly twofold AQ4 concentration was obtained in the 
tumors treated with the targeted trimodal nanosystem com-
pared to that of control without siHIF-1α (c(RGDfK)-ppGO/VP-
AQ4N) (Figure 7F). As siHIF-1α did not confer more hypoxia 
in this scenario (48 h after irradiation) (Figure 7A), such effect 
of siHIF-1α may be mainly ascribed to its role of upregulating 
CYP450 reductases in that duration, through HIF-1α inhibition 
(Figures 4B–F and 7B–E), for strengthened AQ4N activation in 
tumors.
Taken together, these data demonstrated that both VP and 
siHIF-1α can effectively promote the efficacy of AQ4N, war-
ranting a successful trimodal anticancer therapy. It should be 
noted that although the trimodal nanosystem was designed 
mainly to target the tumor vessels, the treatment may not be 
restricted to only perivascular tissues. AQ4N with its high 
penetrating property can spread deeply into the tumor tissue 
for enhanced drug exposure and killing of the hypoxic tumor 
cells in the inner region.[44] Moreover, it showed that HIF-1α 
expression in PC-3 tumors treated with the targeted trimodal 
nanosystem (with siHIF-1α) was remarkably suppressed to 
≈20% level of that treated with the targeted nanosystem without 
siHIF-1α (c(RGDfK)-ppGO/VP-AQ4N) (Figure 7B,C). This 
observation indicated that siHIF-1α delivered by the nano-
system can exert its function (HIF-1α suppression) in a wider 
tumor region. Furthermore, VTP-induced exacerbated hypoxia 
in the region distant from the vessels can directly kill the tumor 
cells and lead to tumor regression, which is the major rationale 
for VTP to treat solid tumors in clinic.[2,45] The histopatholog-
ical examination also demonstrated that the targeted trimodal 
nanosystem resulted in widespread apoptosis in the tumors 
(Figure S13, Supporting Information).
4. Conclusion
In conclusion, we have developed an interlocking trimodal gra-
phene-oxide-based nanosystem to improve VTP, by targeting 
tumor hypoxia with HAP (AQ4N) and siHIF-1α. Meanwhile, 
our study offers a new way to enhance HAP efficacy, which is 
achieved by nanoparticle-mediated VTP to induce aggravated 
hypoxia and siHIF-1α intervention to upregulate the expres-
sion of CYP450 (the key HAP-activating reductases). Our 
therapeutic strategies present promising nanomaterial-based 
approaches towards the clinical applications of both VTP, which 
was recently approved for solid tumor,[4b] and HAPs, which are 
experiencing bottleneck in clinical trials due to the compro-
mised prodrug activation under low levels of tumor hypoxia in 
some clinical settings.[13b]
5. Experimental Section
Materials, Cell Culture, and Animals: AQ4N was purchased from Tocris 
Bioscience (Bristol, UK). AQ4, branched PEI (MW 25 kDa), EDC, NHS, 
suberic acid bis (3-sulfo-N-hydroxysuccinimide ester) sodium salt (BS3), 
FITC conjugated lectin from Bandeiraea simplicifolia, NADPH, ethidium 
bromide, and 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) 
were from Sigma-Aldrich (St. Louis, MO). VP was supplied by Selleck 
(Shanghai, China). Graphene was purchased from JCNANO (Nanjing, 
China). Eight-armed amine-terminated polyethylene glycol (PEG, MW 
10 kDa) was supplied from JenKem (Beijing, China). Cy7-NHS was 
from Bridgen (Beijing, China). c(RGDfK) peptide was synthesized by 
GL Biochem (Shanghai, China). FAM-labeled siRNA targeting HIF-1α 
(siHIF-1α, antisense strand, 5′-UGUAGUAGCUGCAUGAUCGdTdT-3′) 
and negative control siRNA with a scrambled sequence (siNC, 
5′-GACUACUGGUCGUUGAACU dTdT-3′) were synthesized by 
GenePharma (Shanghai, China). Rabbit anti-HIF-1α antibody 
was supplied by Cell Signaling Technology (Danvers, MA). Rabbit 
anticytochrome P450 1A1 and 2B6 antibodies were purchased from Abcam 
(Hong Kong). Rabbit antimouse CD31 antibody and Rat Pooled Liver 
Microsomes Male were purchased from BD Biosciences (San Jose, CA). 
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Double distilled water was purified using a Millipore simplicity system 
(Millipore, Bedford, MA). All other chemicals were of analytical grade 
and used without further purification. A fiber coupled laser diode with 
640 mW output at 690 nm (Inter-Diff Optoelectronics, Shanghai, 
China) was used. The exact optical powers of lasers used in this study 
were corrected and recorded by a 690 nm laser energy meter (Inter-Diff 
Optoelectronics, Shanghai, China).
Primary HUVECs and M200 medium with LSGS were obtained from 
Life Technologies (Carlsbad, CA). Cells at 3–5 passages were used in the 
experiments. Human PC-3 prostate cancer cell line was obtained from 
the American Type Culture Collection (Manassas, VA) and cultured in 
DMEM/F-12 medium (Gibco, Life Technology) supplemented with 10% 
FBS and antibiotics (100 mg mL−1 of streptomycin and 100 U mL−1 of 
penicillin) at 37 °C in a humidified incubator with 5% CO2.
Male BALB/c nude mice (≈20 g) were provided by Shanghai 
Laboratory Animal Center (Chinese Academy of Sciences, Shanghai, 
China). The animal experiment designed in this study was approved 
by the ethical committee of Shanghai Jiao Tong University School of 
Medicine (SJTU-SM).
Preparation and Characterization of Targeted Trimodal Nanosystem 
(c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α): GO was synthesized according 
to previously reported modified Hummers method using graphene as 
the original material.[46] For the preparation of nanoscale PEGylated GO 
(PEG-GO, pGO), the GO solution (1 mg mL−1) was mixed with eight-
armed NH2-terminated PEG (3 mg mL−1) and sonicated for 5 min. Then, 
EDC (1 mg mL−1) was added to the mixture for 30 min sonication. After 
that, the mixture was added with NHS (1.2 mg mL−1) for another 5 min 
sonication, and was stirred gently at room temperature (RT) for 12 h. 
Then the mixture was washed 3–5 times with deionized water using 
100 KDa Milli-Q membrane filter (Millipore, Bedford, MA) (4000 r min−1, 
10 min), obtaining the pGO re-suspended in water.
pGO in water was sequentially mixed with verteporfin (VP, 
0.75 mg mL−1) and AQ4N (1 mg mL−1) and stirred at RT for 12 h, 
respectively. The obtained pGO/VP-AQ4N was stirred at RT for another 
30 min following the addition of c(RGDfK) peptide (0.4 mg mL−1) 
and BS3 (3.5 mg mL−1). After 3–5 times washing, the c(RGDfK)-pGO/
VP-AQ4N mixture was sonicated with PEI (5 mg mL−1) for 5 min. Then, 
EDC was added at final concentration of 2.5 mg mL−1, and the mixture 
was stirred at RT for 6 h. Then, the resulted c(RGDfK)-ppGO/VP-AQ4N 
mixture was washed five times and re-suspended.
To study HIF-1α siRNA (siHIF-1α) loading on the c(RGDfK)-ppGO/
VP-AQ4N complexes, a gel electrophoresis assay was performed after 
incubation of c(RGDfK)-ppGO/VP-AQ4N with siHIF-1α at different 
N/P ratios (2.5, 5, 10, 20, 40, 80, and 120). Different amounts of the 
c(RGDfK)-ppGO/VP-AQ4N solution were mixed with 800 ng of the 
siHIF-1α solution in equal volume, followed by incubation for 30 min at 
RT. The complexes were electrophoresed in 1% (w/v) agarose containing 
ethidium bromide (0.5 µg mL−1) with TAE buffer (Tris-acetate-EDTA) at 
120 v for 30 min. The gel was imaged by an Odyssey Fc Image System 
(LI-COR, Lincoln, NE) to identify the optimal N/P ratio.
For the preparation of empty ppGO (PEI-PEG-GO), c(RGDfK)-ppGO, 
c(RGDfK)-ppGO loading only one or two molecules, and nontargeted 
trimodal nanosystem (ppGO/VP-AQ4N-siHIF-1α), the preparation 
procedure was same to that for the targeted trimodal nanosystem 
except the addition of VP, AQ4N, PEI, or c(RGDfK) if it was required. 
The concentrations of GO, pGO, and ppGO were quantified by their 
absorbance at 230 nm as previously reported.[46] The contents of PEI and 
PEG in the nanocarrier (ppGO) were also quantified. PEI was assayed 
using the cuprammonium complex method.[29] The PEG content was 
determined using the PEGylated protein ELISA kit (Enzo Life Sciences, 
Farmingdale, NY).[30] The c(RGDfK) assay was performed using the 
CBQCA Protein Quantitation Kit (Thermo Fisher Scientific, Shanghai, 
China),[31] then the c(RGDfK) content in the targeted nanocarrier 
(c(RGDfK)-ppGO) can be estimated.
The morphology of the GO-based nanosystem was observed 
using AFM. The size and zeta potential of the various nanoparticles 
was measured with a Zetasizer Nano ZS instrument (Malvern, 
Worcestershire, UK). Drug loading (DL%) was expressed as the 
percentage of the drug amount found in the nanoparticles. The content 
of VP and AQ4N were determined from the absorbance at 410 and 
610 nm, respectively in the UV–vis–NIR spectra, after subtracting the 
absorption contribution of corresponding background according to the 
literature.[47] The colloidal stability of nanoparticles was evaluated in 
pure PBS (pH 7.4, 0.01 m) and PBS with 10% FBS at 37 °C according 
to the literature,[48] and the hydrodynamic size of the nanoparticles was 
examined at 24 and 48 h, respectively (n = 3).
Targeted Uptake of c(RGDfK)-ppGO/VP in HUVECs and PC-3 Cells: 
For cell uptake examination, HUVECs (a cell model mimicking tumor 
vascular ECs) and PC-3 cells were cultured at a density of 5 × 103 cells 
per well in 96-well plates, respectively. When the cells reached about 
80% confluence, the culture medium was replaced by c(RGDfK)-
ppGO/VP or ppGO/VP in medium at nanoparticle concentration of 
10 µg mL−1 or 50 µg mL−1 in 200 µL for 2 h, respectively. After removing 
the nanoparticles and washing the wells three times with PBS, the cells 
were fixed by 4% formaldehyde solution for 15 min, and the cell nuclei 
were stained with 0.1 µg mL−1 DAPI for 8 min. Then, cellular uptake 
was observed and assayed by quantifying the intracellular fluorescence 
intensity of VP (Ex: 650 nm, Em: 690 nm) on the Thermo Scientific 
ArrayScan XTI High Content Analysis (HCA) Reader.[49] The quantitative 
results were acquired based on 15 random microscope fields in each 
well, and the tests were replicated for four times.
Cell Viability after Photodynamic Treatment with c(RGDfK)-ppGO/VP In 
Vitro: Briefly, HUVECs and PC-3 cells were cultured at a density of 5 × 
103 cells per well in 96-well plates, respectively. After 24 h incubation at 
37 °C, the culture medium was replaced by 200 µL of c(RGDfK)-ppGO/
VP or ppGO/VP in medium at VP dose of 0.001 × 10−6, 0.01 × 10−6, 0.1 × 
10−6, and 1 × 10−6 m for 6 h, respectively. Then, cells were irradiated by 
the 690 nm laser for 10 min at the power density of 30 mW cm−2, and 
cultured in fresh medium for another 24 h. Then the cell viabilities were 
quantitatively determined using Cell Counting Kit-8 (CCK-8) assay.[49] 
Also the cell viabilities were qualitatively evaluated using LIVE/DEAD cell 
viability/cytotoxicity kit (Life technology, Carlsbad, CA).[50] In this assay, 
calcein-AM is enzymatically converted into green fluorescent calcein in 
live cells, while ethidium homodimer stains the nuclei of dead cells with 
red fluorescence. After irradiation treatments and culture for another 
24 h, the medium was replaced with 1 mL PBS containing 0.5 µg mL−1 
calcien-AM (Ex: 488 nm and Em: 515 nm) and 5 µg mL−1 ethidium 
homodimer (Ex: 535 nm and Em: 615 nm), to stain live and dead cells. 
Then, the cells were photographed under the microscope. The tests were 
replicated for three times. ADMA was also used to detect the production 
of singlet oxygen and verify the PDT performance.[33]
Lysosomal Escape of c(RGDfK)-ppGO/FAM-siHIF-1α: Escape from 
the lysosomes is important for effective delivery of siRNA into the 
cytosol. PC-3 cells were incubated with c(RGDfK)-ppGO/FAM-siHIF-1α 
(green, Ex: 488 nm, Em: 520 nm) for 0.5–4 h, respectively. siHIF-1α at 
150 × 10−9 m was used in this test. The lysosomes were labeled with 
LysoTracker Red DND-99 (Life technology, Carlsbad, CA) (red, Ex: 
577 nm, Em: 590 nm). Time-dependent intracellular trafficking of 
c(RGDfK)-ppGO/FAM-siHIF-1α was detected under CLSM (LSM-510, 
Carl Zeiss AG, Oberkochen, Germany).
Expression of HIF-1α, CYP1A1, and CYP2B6 in Tumor Cells and 
Xenograft: Protein expressions were examined using western blot. For 
in vitro assay, PC-3 cells were seeded in 6-well plates (1 × 105 cells per 
well) and incubated for 24 h (normoxia, 5% CO2). Then the cells were 
incubated with c(RGDfK)-ppGO/siHIF-1α, and other controls including 
ppGO/siHIF-1α, empty c(RGDfK)-ppGO, and c(RGDfK)-ppGO/siNC 
for 12 h under hypoxia (1% O2, 5% CO2 balanced with N2), respectively 
(n = 3). siHIF-1α at 150 × 10−9 m was used in all the groups with the 
molecule involved. For in vivo assay, 48 h after the PDT treatment 
(690 nm, 50 mW cm−2, 20 min), three nude mice from each group 
(c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α, c(RGDfK)-ppGO/VP-AQ4N, and 
ppGO/VP-AQ4N-siHIF-1α) were sacrificed, and tumors were excised. 
Cells alone under hypoxia were used as control.
Protein extraction from cells or homogenized tumors was performed 
using RIPA Lysis Buffer supplemented with Complete Protease 
Inhibitor Cocktail Tablets (Roche, Rotkreuz, Switzerland).[51] The protein 
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concentrations were determined with BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL). Equivalent amount (30 µg) of protein from 
different samples were applied to 10% SDS-PAGE, and then electrically 
transferred (220 mA, 120 min) onto Immobilon-P membranes 
(Millipore, Bedford, MA). Then, the membranes were blocked in tris-
buffered saline (TBS) with 0.05% Tween-20 (TBST) containing 5% 
bovine serum albumin (BSA) for 1 h at RT, and then incubated in TBST 
containing 1% BSA and primary antibody against HIF-1α (1:1000), 
CYP1A1 (1:1000) and CYP2B6 (1:1000) overnight at 4 °C, respectively. 
Then, the membranes were washed thrice with TBST and incubated with 
horseradish peroxidase-conjugated goat antirabbit antibody (1:5000, Cell 
Signaling Technology, Danvers, MA) for 1 h at RT. Finally, the membranes 
were imaged by an Odyssey Fc Image System (LI-COR, Lincoln, NE).
AQ4N Toxicity to PC-3 Cells in the Presence of siHIF-1α and Exogenous 
CYP450 from Liver Microsomes: PC-3 cells were cultured at a density of 
5 × 103 cells per well in 96-well plates. After 24 h incubation at 37 °C, the 
cells were incubated with c(RGDfK)-ppGO nanoparticles carrying both 
AQ4N (0.4 × 10−6 and 2 × 10−6 m) and siHIF-1α (150 × 10−9 m) under 
hypoxia (1% O2, 5% CO2 balanced with N2) for 4 h, and then the cells 
were rinsed with PBS and incubated in normoxia (95% air, 5% CO2) for 
another 24 h. The nanoparticles carrying AQ4N or siHIF-1α alone, and 
the empty vehicle (c(RGDfK)-ppGO) were also included in the tests. The 
PC-3 cells alone under hypoxia was set as control. The cell viabilities were 
detected using CCK-8 assay. The tests were replicated for three times.
Also, PC-3 cells were treated with c(RGDfK)-ppGO or ppGO 
nanoparticles carrying AQ4N (0.08 × 10−6, 0.4 × 10−6, and 2 × 10−6 m) 
and exposed under normoxia or hypoxia with/without CYP450-
contained Rat Pooled Liver Microsomes Male (3 mg mL−1) plus NADPH 
(5 × 10−3 m) for 4 h. Then, the cells were rinsed with PBS and incubated 
in normoxia for another 24 h. The PC-3 cells alone under normoxia was 
set as control. The cell viabilities were detected using CCK-8 assay. The 
tests were replicated for three times.
In Vivo Tumor Targeting of the Nanosystem in PC-3 Xenograft: Cy7-NHS 
was conjugated to the amines of PEI of c(RGDfK)-ppGO. The real-time 
tumor accumulation of Cy7-labeled c(RGDfK)-ppGO in male BALB/c 
nude mice bearing subcutaneous PC-3 xenografts (150 mm3) on the 
right hind limb were monitored under the Xenogen IVIS 200 (Caliper 
Life Sciences, MA) imaging system.[52] Three mice from each group 
were injected through the caudal vein with 0.4 mg kg−1 of Cy7-labeled 
c(RGDfK)-ppGO or ppGO, respectively. After 1, 2, 8, and 24 h, the mice 
were anaesthetized and imaged with an excitation bandpass filter at 
750 nm and an emission at 790 nm. The exposure time for each image 
was 3 s. The blocking effect of 50-fold molar excess c(RGDfK) on the 
tumor tissue targeting was also evaluated.
The targeted distribution of the loaded three active molecules (VP, 
AQ4N, and siHIF-1α) in tumors was also determined. The nanoparticles 
(ppGO/VP-AQ4N-siHIF-1α and c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α; 
VP 1 mg kg−1, AQ4N 5 mg kg−1, and Cy7-labeled siHIF-1α 0.5 mg kg−1) 
were i.v. injected to the mice bearing PC-3 tumor (n = 3). After 2 h, the 
accumulation of Cy7-labeled siHIF-1α in tumors were examined using the 
Xenogen IVIS 200 imaging system as described in the literature.[53] For VP 
and AQ4N assay, the mice were sacrificed, and tumors were excised and 
homogenized. Protein precipitation was produced with three volumes 
of acetonitrile (0.1% acetic acid) for AQ4N and VP sample preparation. 
Analyses were performed on a QTRAP 5500 LC-MS/MS System (AB Sciex, 
USA) equipped with Shimazu LC-20 HPLC system (Shimazu, Japan). 
A Waters XBridge C18 Column (2.1 mm × 50 mm, 3.5 µm) was used 
for analyte separation. Gradient elution with a mobile phase consisting 
of water and acetonitrile (0.1% acetic acid in both components, 
0.4 mL min−1) was used for the separation. For VP assay, a gradient 
elution with 50/50 (0–0.5 min), 25/75 (0.5–1 min), 5/95 (1–4.5 min) 
and 50/50 (4.5–7.5 min) (water/acetonitrile, v/v) composition was used. 
For AQ4N detection, a gradient elution with 98/2 (0–0.5 min), 5/95 
(0.5–2 min), 5/95 (2–5 min), and 98/2 (5–7.5 min) composition was 
adopted. AQ4N (m/z 445.2–323.0, DP 90 V, EP 10 V, CE 30 V), VP (m/z 
719.2–645.2, DP 90 V, EP 10 V, CE 58 V) and IS (paclitaxel, m/z 854.4–
286.1, DP 190 V, EP 14 V, CE 21 V) were monitored. Data processing of 
MS was performed on the software package (AB Sciex, USA).
Mouse Model and Treatment Protocol: Male BALB/c nude mice were 
subcutaneously inoculated with PC-3 cells (5 × 106 cells per mouse). 
When the tumors grew to ≈100 mm3, the mice were randomized into 
10 groups (n = 8): (1) saline (Control); (2) empty c(RGDfK)-ppGO; 
(3) c(RGDfK)-ppGO/VP; (4) c(RGDfK)-ppGO/AQ4N; (5) c(RGDfK)-
ppGO/siHIF-1α; (6) c(RGDfK)-ppGO/VP-AQ4N; (7) c(RGDfK)-ppGO/
VP-siHIF-1α; (8) c(RGDfK)-ppGO/AQ4N- siHIF-1α; (9) ppGO/
VP-AQ4N-siHIF-1α; (10) c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α. VP 
(1 mg kg−1), AQ4N (5 mg kg−1), and siHIF-1α (0.5 mg kg−1) were given 
in all cases involved.
At 2 h after nanoparticle injection, the tumors were irradiated with 
laser (690 nm, 50 mW cm−2) for 20 min 48 h after irradiation, three 
mice from each group were sacrificed, and the tumors were removed 
and processed for paraffin sections and histopathological examination. 
Tumor cell apoptosis and proliferation were identified using ApopTag 
Peroxidase In situ Apoptosis Detection Kit (Merck Millipore, Billerica, 
MA) and mouse antihuman antibody against PCNA (Santa Cruz, CA), 
respectively. Quantitative histopathological assay was performed using 
Image-Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD). Tumor 
sizes (n = 5) were monitored with a digital caliper every day throughout 
the study, and tumor volume was calculated as volume (mm3) = length × 
width2/2. In addition, tumor volume DT was calculated with the following 
equation:[54] DT =T × log 2/(log VF – log Vi), where VF is the final tumor 
volume, Vi is the initial tumor volume at drug treatment time point, and 
T is the time difference between the initial and the final day. The body 
weights of all mice were measured every 3 d for two weeks till day 15.
Detection of Functional and Whole Vessels in Tumors: At 24 and 48 h 
after irradiation, FITC-labeled Bandeiraea simplicifolia lectin (0.1 mg kg−1) 
was injected into PC-3 tumor bearing mice via tail vein to characterize 
functional vessels.[40] At 20 min after lectin injection, three nude mice 
from each group (c(RGDfK)-ppGO, ppGO/VP-AQ4N-siHIF-1α and 
c(RGDfK)-ppGO/VP- AQ4N-siHIF-1α) were sacrificed. The treatment 
with c(RGDfK)-ppGO/VP-AQ4N-siHIF-1α but no irradiation was also 
included as control. The tumors were removed and processed for sections 
and immunofluorescence staining with rabbit antimouse CD31 antibody 
(1: 200) for whole tumor vascular ECs.[40] The secondary antibody was 
Alexa Flour 647 donkey antirabbit IgG (Life Technologies, Shanghai, 
China). The slides were observed for tumor total vessels and functional 
vessels under CLSM for CD31 (Ex: 650 nm, LP Em: 668 nm) and FITC-
labeled lectin (Ex: 495, Em: BP 505–550 nm), respectively. The percentage 
of lectin and CD31 dual-positive functional vessels were estimated using 
Image-Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD).
Tumor Vascular Perfusion: The Vevo 2100 micro-ultrasound imaging 
system (FujiFilm VisualSonics, Toronto, Canada) was used to evaluate the 
tumor vascular perfusion.[55] Briefly, 24 h after irradiation, three mice from 
each group (c(RGDfK)-ppGO, ppGO/VP-AQ4N-siHIF-1α and c(RGDfK)-
ppGO/VP-AQ4N-siHIF-1α) were anaesthetized with the mixture of 3.0% 
isofluorane and medical air mixture and placed on the warmed platform. 
The MicroMarker contrast agent (FujiFilm VisualSonics, Toronto, 
Canada) was prepared with a final concentration of 2 × 109 microbubbles 
in 1 mL saline solution, and a 50 µL bolus was delivered to the mice 
via tail vein catheter, and then the image acquisition started. Three 
representative characteristic parameters (Wash-in Area Under the Curve, 
Peak Enhancement, Wash-in Perfusion Index) describing the speed and 
extent of the vascular perfusion were calculated by the software Vevo LAB 
1.7 (FujiFilm VisualSonics, Toronto, Canada).[49]
Tumor Oxygenation: At 24 and 48 h after irradiation, a fiber-optic 
oxygen sensor (Oxylite, Oxford Optronix, Abingdon, UK), based on 
the principle of oxygen quenching of fluorescence, was used for tissue 
oxygenation pressure (pO2) monitoring in the tumors as previously 
described.[56] Three mice from each group were tested.
AQ4N Activation into AQ4 after Treatment with Targeted Trimodal 
Nanosystem plus Irradiation: AQ4N can be reductively activated into 
AQ4 under hypoxic conditions by several cellular enzymes, such as 
CYP450. At 24 and 48 h after irradiation, three nude mice from each 
group (c(RGDfK)-ppGO/AQ4N, c(RGDfK)-ppGO/AQ4N-siHIF-1α, 
c(RGDfK)-ppGO/VP-AQ4N, ppGO/VP-AQ4N-siHIF-1α, c(RGDfK)-
ppGO/VP-AQ4N-siHIF-1α; VP 1 mg kg−1, AQ4N 5 mg kg−1, and 
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siHIF-1α 0.5 mg kg−1 in all groups with drug involved) were sacrificed, 
and tumors were excised and homogenized. Protein precipitation was 
produced with three volumes of acetonitrile for AQ4 sample preparation. 
Analyses were performed on an Agilent 6410 triple quadrupole mass 
spectrometer (Agilent Technologies, USA) equipped with electrospray 
ionization and an Agilent 1200 HPLC system (Agilent Technologies, 
USA). A Merck ZIC-HILIC column (2.1 mm × 100 mm, 3.5 µm) was used 
for analyte separation. Isocratic elution with a mobile phase consisting 
of acetonitrile and water (60: 40, v/v, the aqueous phase contained 0.1% 
formic acid and 10 × 10−9 m ammonium formate, 0.3 mL min−1) was 
used for the separation. Two MRM transitions, AQ4 (m/z 413.2–72.2, 
fragmentor 140 eV, collision energy 20 eV) and IS (glycyrrhetic acid, m/z 
471.5–177.1, fragmentor 160 eV, collision energy 30 eV) were monitored. 
Data processing of MS was performed on the MassHunter software 
package (VersionB.04.00, Agilent Technologies).
Statistical Analysis: Statistical analysis was conducted using GraphPad 
Prism 6.0 software (La Jolla, CA). Differences between groups were 
examined using Student’s t-test or ANOVA with Tukey’s multiple 
comparison tests. Differences were considered significant if p value was 
less than 0.05.
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